HK Stock Market Move | Hongteng Precision (06088) surged nearly 10% during midday trading as management raised guidance based on strong prospects for AI servers.
Hungteng Precision (06088) rose nearly 10% intraday, up 8.97% as of the time of writing, at 5.95 Hong Kong dollars, with a turnover of 3.9 billion Hong Kong dollars.
Hongteng Precision (06088) rose nearly 10% in midday trading, up 8.97% as of the time of drafting, at HK$5.95, with a turnover of HK$390 million.
In terms of news, Hongteng Precision recently released its annual performance, with revenue of US$5.03 billion, a year-on-year increase of 12.39%; the company's attributable profit was US$156 million, a year-on-year increase of 1.51%. The revenue of cloud network infrastructure business grew by 37.6% year-on-year, primarily driven by the demand for AI driving an increase in shipments of copper-based parts in the server market; the revenue of the automotive business increased by 94.0% year-on-year, mainly due to the full-year contribution of Germany's Auto-Kabel Group.
Zhongyin International released a research report stating that during the performance conference call, Hongteng Precision's management reiterated a positive view on the momentum of cloud/data centers, based on large-scale AI server upgrades and mass production of new products in FY26-28E. The management guided for a 70% year-on-year growth in cloud/data center revenue in 2026E, and raised the guidance for the proportion of cloud business revenue in FY26-28E to 20% mid-range/20% high-range/30% low-range.
Related Articles

Country Garden (02007) issued a total of 15.0569 million shares due to the convertible bonds being converted.

SEAZEN(01030): Lv Xiaoping resigns as executive director

Haisco Pharmaceutical Group (002653.SZ): HSK46575 tablet is approved for new indications in drug clinical trials.
Country Garden (02007) issued a total of 15.0569 million shares due to the convertible bonds being converted.

SEAZEN(01030): Lv Xiaoping resigns as executive director

Haisco Pharmaceutical Group (002653.SZ): HSK46575 tablet is approved for new indications in drug clinical trials.






